Osteoarthritis, Knee Clinical Trial
— RAPTOROfficial title:
Rural Access to Physical Therapy for Osteoarthritis Rehabilitation
This is a pilot study involving a hybrid in-person + telerehabilitation intervention for rural adults with knee osteoarthritis. The primary purpose is to demonstrate feasibility and safety of the RAPTOR program, and the secondary purpose is to estimate clinical effectiveness of the RAPTOR program on participants' pain, function, and quality of life.
Status | Recruiting |
Enrollment | 27 |
Est. completion date | September 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Potential participants who meet all of the following criteria will be included: - Participant meets American College of Rheumatology criteria for the clinical diagnosis of knee osteoarthritis - Participant's home address is in a rural (non-core) western Pennsylvania county - Participant is willing to travel to Centers for Rehab Services - Bedford clinic for two face-to-face sessions with a licensed physical therapist - Participant has access to high-speed internet and/or LTE wireless service and a device (tablet, computer, or smartphone) to access the telerehabilitation platform - Participant is aged 40 or over Potential participants will be excluded if any of the following criteria apply: - Chronic neurological disorder affecting balance or coordination - Any other disorder that affects balance or gait - Two or more falls in the past 12 months, OR sought medical attention for any fall within the past 12 months |
Country | Name | City | State |
---|---|---|---|
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pittsburgh | University of Pittsburgh Medical Center Rehabilitation Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment Target | The investigators' recruitment target is 27 participants, and this outcome will be successful upon enrollment of the 27th participant. This outcome will be used as one component of the overall summary outcome of "feasibility", which is defined as success in all 5 primary outcomes. | Through study completion, which is anticipated to take approximately 1 year. | |
Primary | Visit Attendance (75% or higher) | The percentage of physical therapy visits attended, divided by the number of scheduled visits (10) for each participant. This outcome will be successful if mean visit attendance among all participants is at least 75%. This outcome will be used as one component of the overall summary outcome of "feasibility", which is defined as success in all 5 primary outcomes. | Through study completion, which is anticipated to take approximately 1 year. | |
Primary | Telehealth Usability Questionnaire | The Telehealth Usability Questionnaire (5/7) is a self-reported questionnaire used to assess participant satisfaction with the telehealth services received. It contains 21 items, each rated on a 7-point scale ranging from "strongly disagree" (1 point) to "strongly agree" (7 points). The items are summed to create a total score ranging from 7 - 147 points, with higher numbers indicating greater usability of the telehealth services. This outcome will be successful if the average item rating across all participants is at least 5/7. This outcome will be used as one component of the overall summary outcome of "feasibility", which is defined as success in all 5 primary outcomes. | Measured at post-treatment (last visit, approximately 10 weeks after enrollment) | |
Primary | Study-Related Adverse Events / Serious Adverse Events | This outcome will be successful if there are zero study-related adverse events and serious adverse events among the 27 participants. This outcome will be used as one component of the overall summary outcome of "feasibility", which is defined as success in all 5 primary outcomes. | Through study completion, which is anticipated to take approximately 1 year. | |
Primary | Clinically Important Improvement on ONE Functional Outcome Measure | The final component of the overall primary outcome of feasibility will be met if each participant achieves mean improvement on at least one functional outcome measure that exceeds the minimum clinically important difference. This may occur on a self-reported outcome measure (the KOOS, described below) or a performance-based outcome measure (30-second chair stand test, timed stair climb test, Timed Up and Go test, 40-meter fast-paced walk test, 6-minute walk test). All of these outcome measures are individually considered to be Secondary Outcome Measures and are described below in greater detail. | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) | |
Secondary | Functional outcome measure: 30-second chair stand test | Measures the number of times the participant can stand up and sit down from a chair in a 30-second period. | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) | |
Secondary | Functional outcome measure: Timed stair climb test | Measures the number of seconds it takes the participant to climb and descend 1 full flight of standard stairs. | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) | |
Secondary | Functional outcome measure: Timed Up and Go (TUG) | Measures the number of seconds it takes for the participant to stand up from a chair, walk 3 meters, turn around, walk 3 meters back to the chair, and sit back down in the chair. | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) | |
Secondary | Functional outcome measure: 40-meter fast-paced walk test | Measures the number of seconds it takes the participant to walk 40 meters at what the participant considers to be a "fast pace". | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) | |
Secondary | Functional outcome measure: 6-minute walk | Measures the number of meters the participant can walk in 6 minutes at a self-selected pace. | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) | |
Secondary | Functional outcome measure: Change from baseline in KOOS (Knee Injury and Osteoarthritis Outcome Score) to Post-Treatment | The KOOS is a self-reported survey containing five subscales, each of which is considered separately (i.e. there is no "total" KOOS score). The investigators will use three of the KOOS subscales: Pain (Minimum Detectable Change [MDC] 13.4 points for people with KOA), Activities of Daily Living (MDC 15.4 points), and Quality of Life (MDC 21.1 points). Each subscale is measured on a 0-100 scale, with lower scores indicating worse symptoms / worse function. | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03895489 -
Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses
|
N/A | |
Completed |
NCT03660943 -
A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain
|
Phase 3 | |
Completed |
NCT04531969 -
Comparison of Outpatient and Inpatient Spa Therapy
|
N/A | |
Completed |
NCT02848027 -
Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment
|
Phase 3 | |
Completed |
NCT05160246 -
The Instant Effect of Kinesiology Taping in Patients With Knee OA
|
N/A | |
Recruiting |
NCT06080763 -
Biomechanics and Clinical Outcomes in Responders and Non-Responders
|
||
Completed |
NCT03643588 -
The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain
|
N/A | |
Active, not recruiting |
NCT05100225 -
Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis
|
Phase 2 | |
Active, not recruiting |
NCT04061733 -
New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis
|
N/A | |
Completed |
NCT04051489 -
A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
|
||
Recruiting |
NCT05546541 -
Epidemiology and Nutrition
|
||
Recruiting |
NCT05447767 -
Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg
|
Phase 2 | |
Not yet recruiting |
NCT04448106 -
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
|
Phase 2 | |
Not yet recruiting |
NCT03225911 -
Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis
|
N/A | |
Completed |
NCT05070871 -
A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women
|
N/A | |
Completed |
NCT05703087 -
Positive Cueing in Knee Arthroplasty.
|
N/A | |
Not yet recruiting |
NCT06042426 -
Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population
|
Phase 4 | |
Not yet recruiting |
NCT02865174 -
Topical Tranexamic Acid and Floseal® in Total Knee Arthroplasty
|
Phase 4 | |
Completed |
NCT02901964 -
Effect of Strengthening the Hip Abductor in Patients With Knee Osteoarthritis: Randomized Controlled Trial
|
N/A | |
Terminated |
NCT02909257 -
Motor-Sparing Femoral Nerve Block Dose
|
Phase 4 |